{
  "id": "MISSION-500-182-1771352772033",
  "itemType": "priorityAction",
  "questionStem": "The nurse in the emergency department is caring for a client with a suspected ischemic stroke. The nurse has received a STAT order to administer alteplase (tPA) at 14:40. Based on the provided client data, which action is the priority for the nurse to take at this time?",
  "options": [
    {
      "id": "opt_5",
      "text": "Request a social work consult to address the client's living situation."
    },
    {
      "id": "opt_2",
      "text": "Hold the alteplase infusion and immediately notify the provider of the platelet count."
    },
    {
      "id": "opt_1",
      "text": "Administer labetalol 10 mg IV push as prescribed."
    },
    {
      "id": "opt_3",
      "text": "Confirm the client's weight to calculate the correct alteplase dose."
    },
    {
      "id": "opt_4",
      "text": "Initiate the alteplase infusion as ordered by the provider."
    },
    {
      "id": "opt_6",
      "text": "Place a second large-bore IV catheter in the unaffected arm."
    }
  ],
  "exhibits": [
    {
      "id": "exhibit_1",
      "type": "NursesNotes",
      "title": "Nurses' Notes",
      "content": "**14:00:** Client, a 68-year-old male, arrives via EMS after being found on his kitchen floor by a neighbor. The neighbor, who performs daily wellness checks, reports last speaking with the client by phone 'around 21:00 last night.' Client is drowsy but arousable, with evident expressive aphasia and right-sided hemiparesis. NIHSS score calculated as 16. The client lives alone in a rural community with limited transportation options."
    },
    {
      "id": "exhibit_2",
      "type": "VitalSigns",
      "title": "Vital Signs",
      "data": [
        {
          "time": "14:05",
          "BP": "192/105",
          "HR": "88",
          "RR": "18",
          "SpO2": "96% (Room Air)",
          "Temp": "37.1°C (98.8°F)"
        },
        {
          "time": "14:20",
          "BP": "188/102",
          "HR": "90",
          "RR": "18",
          "SpO2": "95% (Room Air)",
          "Temp": "37.1°C (98.8°F)"
        },
        {
          "time": "14:35",
          "BP": "184/98",
          "HR": "92",
          "RR": "20",
          "SpO2": "95% (Room Air)",
          "Temp": "37.1°C (98.8°F)"
        }
      ]
    },
    {
      "id": "exhibit_3",
      "type": "LabResults",
      "title": "Laboratory Results (STAT Panel)",
      "data": [
        {
          "lab": "WBC",
          "value": "8.5 x 10³/μL",
          "range": "4.5-11.0"
        },
        {
          "lab": "Hemoglobin",
          "value": "14.2 g/dL",
          "range": "13.5-17.5"
        },
        {
          "lab": "Platelets",
          "value": "75,000/mm³",
          "range": "150,000-450,000"
        },
        {
          "lab": "INR",
          "value": "1.1",
          "range": "0.8-1.2"
        },
        {
          "lab": "Glucose (POC)",
          "value": "130 mg/dL",
          "range": "70-140"
        },
        {
          "lab": "Creatinine",
          "value": "1.0 mg/dL",
          "range": "0.7-1.3"
        }
      ]
    },
    {
      "id": "exhibit_4",
      "type": "DiagnosticFinding",
      "title": "Radiology Report",
      "content": "**Non-contrast Head CT (14:25):**\n\n**FINDINGS:** No evidence of acute intracranial hemorrhage, mass effect, or hydrocephalus. Subtle hypoattenuation noted in the left middle cerebral artery (MCA) territory, suggestive of early ischemic changes. \n\n**IMPRESSION:** Findings consistent with acute ischemic stroke. No hemorrhagic contraindication to thrombolysis."
    },
    {
      "id": "exhibit_5",
      "type": "MAR",
      "title": "Provider Orders",
      "data": [
        {
          "time": "14:40",
          "order": "Alteplase (tPA) IV infusion per institutional stroke protocol. STAT."
        },
        {
          "time": "14:40",
          "order": "Labetalol 10 mg IV push, may repeat x1 for SBP > 185 mmHg or DBP > 110 mmHg."
        },
        {
          "time": "14:40",
          "order": "Admit to Stroke Unit."
        },
        {
          "time": "14:40",
          "order": "Strict NPO."
        }
      ]
    }
  ],
  "answerBreakdown": {
    "correctAnswer": "opt_2",
    "rationales": {
      "analyzeCues": "The client presents with signs of an acute ischemic stroke: expressive aphasia and right-sided hemiparesis, confirmed by a NIHSS score of 16 and CT findings of hypoattenuation in the left MCA territory. While the CT rules out hemorrhage, a critical lab value reveals thrombocytopenia (platelet count 75,000/mm³). Alteplase (tPA) is contraindicated with platelet counts <100,000/mm³ due to the increased risk of intracranial hemorrhage. The elevated blood pressure (184/98 mmHg) is below the threshold requiring immediate treatment before tPA administration, but the thrombocytopenia is an absolute contraindication.",
      "takeAction": "The priority is to prevent a potentially fatal medication error. The nurse must immediately hold the alteplase infusion and notify the provider of the critical platelet count. This allows for re-evaluation of the treatment plan and consideration of alternative therapies, mitigating the risk of hemorrhagic conversion of the stroke.",
      "options": {
        "opt_1": "Incorrect. While the client's blood pressure is elevated, it does not meet the threshold (SBP > 185 mmHg or DBP > 110 mmHg) requiring immediate treatment prior to alteplase administration *if* the client were otherwise eligible. Addressing the absolute contraindication of thrombocytopenia is the priority. Administering labetalol implies the intent to proceed with alteplase, which is unsafe.",
        "opt_2": "Correct. The client's platelet count of 75,000/mm³ is an absolute contraindication to alteplase administration. Alteplase is a thrombolytic agent that works by dissolving clots, but in the presence of thrombocytopenia, the risk of bleeding, particularly intracranial hemorrhage, is significantly increased. Holding the infusion and notifying the provider is crucial to prevent a life-threatening adverse event.",
        "opt_3": "Incorrect. Confirming the client's weight is a standard step in preparing alteplase to ensure accurate dosing. However, this step is irrelevant when the medication is absolutely contraindicated. The priority is to prevent administration of an unsafe medication, not to prepare it correctly.",
        "opt_4": "Incorrect. Initiating the alteplase infusion with a platelet count of 75,000/mm³ is a dangerous error. It directly violates established safety protocols and places the client at high risk for intracranial hemorrhage and death. This action demonstrates a failure to recognize a critical contraindication.",
        "opt_5": "Incorrect. Addressing the client's social situation is important for long-term care and discharge planning, especially considering the client lives alone in a rural area. However, it is not the priority in this acute situation. Ensuring physiological safety by preventing a medication error takes precedence.",
        "opt_6": "Incorrect. Establishing a second IV line can be helpful for administering multiple medications or fluids. However, it does not address the immediate threat posed by the contraindication to alteplase. Preventing a life-threatening medication error is the priority over establishing additional IV access."
      }
    },
    "clinicalPearl": "Always review lab values, especially platelet counts and coagulation studies, before administering alteplase (tPA). Thrombocytopenia (platelet count < 100,000/mm³) is an absolute contraindication due to the increased risk of intracranial hemorrhage. In acute stroke management, time is brain, but safety is paramount.",
    "pathophysiology": "In ischemic stroke, a blood clot blocks an artery supplying blood to the brain, leading to oxygen deprivation and neuronal damage. Alteplase (tPA) is a thrombolytic agent used to dissolve the clot and restore blood flow. However, alteplase increases the risk of bleeding. Thrombocytopenia, a condition characterized by a low platelet count, impairs the body's ability to form blood clots. When alteplase is administered to a thrombocytopenic patient, the risk of uncontrolled bleeding, particularly intracranial hemorrhage, is significantly elevated. This is because platelets are essential for hemostasis, and their deficiency compromises the body's ability to repair damaged blood vessels and stop bleeding. The combination of thrombolysis and impaired clotting mechanisms creates a high-risk scenario for hemorrhagic conversion of the ischemic stroke, leading to severe neurological deterioration and potentially death."
  },
  "sbar": {
    "situation": "68-year-old male in the ED with suspected ischemic stroke, ordered to receive alteplase (tPA) at 14:40.",
    "background": "Client presents with expressive aphasia, right-sided hemiparesis, and NIHSS score of 16. Head CT shows no hemorrhage. Platelet count is 75,000/mm³.",
    "assessment": "Client has thrombocytopenia (platelet count < 100,000/mm³), an absolute contraindication to alteplase administration.",
    "recommendation": "Hold the alteplase infusion immediately and notify the provider of the platelet count to re-evaluate the treatment plan. Consider alternative therapies for stroke management."
  },
  "sentinelStatus": "healed_v2026_v8"
}